ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1112

Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout

Rochella A. Ostrowski1, Elizabeth Araujo2, Richard Hariman3 and Elaine Adams4, 1Division of Rheumatology, Loyola University Medical Center, Maywood, IL, 2Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 3Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 4Rheumatology, Edward Hines Jr Hospital, Veterans Administration, Hines, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, steroids and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration.  No studies have evaluated the ideal dose of steroids for gout flares.  However, occurrences of treatment failure and side effects from treatment warrant an evaluation for the lowest effective dosing.  The goal of this double blinded prospective pilot study is to compare efficacies of a moderate dose and high dose prednisone course in treating acute gout.

Methods:

Male subjects age 18 years and older at Edward Hines Jr Hospital VA with acute gout were included.  Patients with heart failure exacerbation, uncontrolled diabetes mellitus, infection, pseudogout, or chronic prednisone use were excluded.   Subjects were randomized to a high or moderate dose of prednisone (high: 60mg on day 1, decreased by 10mg each day for a 6 day course; moderate: 30mg on day 1, decreased by 5mg each day for 6 days). 

The primary endpoint was improvement in pain at 48 hours based on a 200mm visual analog scale.  Secondary endpoints included the proportion of patients with resolution of synovitis by Day 7; absence of recurrent flares at 28 days; the proportion of patients who returned to baseline pain by day 7; and the number of days to return to baseline pain levels.

An intention-to-treat approach was used for analysis.  Student t-test was used to compare mean values and Fishers exact test was used to compare proportions (STATA 11.1).

Results:

139 patients were screened, and 33 patients were enrolled between September 2007 and December 2014.  All patients enrolled were male, with a mean age of 62.2 (± 11.8) and 63.4 (± 15.8) years in the moderate and high dose groups respectively.  Results are summarized in Table 1.  The mean percent improvement in pain severity at 48 hours was higher in the high dose group (51.9 vs 43.7%), though it did not achieve statistical significance.  Of 26 patients examined at day 7, a higher proportion of patients in the moderate dose group experienced resolution of synovitis, though this finding did not reach statistical significance (0.75 in moderate group vs 0.36 in high group).

The proportion of patients back at baseline pain on day 7 was significantly higher in the moderate dose group (0.73 vs 0.26, p=0.013).  The time to return to baseline pain levels was also shorter in the moderate dose group but did not achieve statistical significance.  

Conclusion:

In this randomized double blinded pilot study, there were no significant differences between the response of acute gout to high dose versus moderate dose prednisone at 48 hours and exam findings on day 7.  Furthermore, the proportion of patients who returned to baseline pain levels was lower in the high dose group, contrary to what investigators hypothesized would occur.  Despite size limitations of this pilot study, our findings warrant larger trials to establish a standardized, evidence based practice for appropriate dosing of steroids in acute gout.

 


Disclosure: R. A. Ostrowski, None; E. Araujo, None; R. Hariman, None; E. Adams, None.

To cite this abstract in AMA style:

Ostrowski RA, Araujo E, Hariman R, Adams E. Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-high-dose-versus-moderate-dose-prednisone-in-the-treatment-of-acute-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-high-dose-versus-moderate-dose-prednisone-in-the-treatment-of-acute-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology